| P50 | author | William L. Irving | Q55186545 |
| | Brian J Thomson | Q83581179 |
| P2093 | author name string | Sam Lattimore | |
| | Nik Howes | |
| P2860 | cites work | Epidemiology of hepatitis C virus infection | Q22305500 |
| | Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. | Q51865940 |
| | The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre | Q59654552 |
| | Now, later or never? Challenges associated with hepatitis C treatment | Q62896203 |
| | Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors | Q26853671 |
| | Global epidemiology of hepatitis C virus infection | Q27860799 |
| | The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide | Q29616215 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 |
| | Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection | Q29620318 |
| | Global burden of disease (GBD) for hepatitis C. | Q35610002 |
| | Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. | Q37232639 |
| | Limited uptake of hepatitis C treatment among injection drug users | Q37238205 |
| | Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care | Q37358615 |
| | A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel | Q37886280 |
| | Boceprevir and telaprevir in the management of hepatitis C virus-infected patients | Q37966762 |
| | Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. | Q39666114 |
| | Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. | Q39808476 |
| | Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. | Q39820916 |
| | Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. | Q39874376 |
| | Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals | Q39910287 |
| | The continuum of hepatitis C testing and care. | Q40231197 |
| | Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). | Q41429836 |
| | Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial | Q42211649 |
| | Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. | Q42999430 |
| | Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs | Q44105883 |
| | Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. | Q45497809 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | hepatitis C | Q154869 |
| P304 | page(s) | ofv218 | |
| P577 | publication date | 2016-01-06 | |
| P1433 | published in | Open Forum Infectious Diseases | Q27725953 |
| P1476 | title | Clinical Care Pathways for Patients With Hepatitis C: Reducing Critical Barriers to Effective Treatment | |
| P478 | volume | 3 | |